<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6473">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014689</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29080</org_study_id>
    <nct_id>NCT01014689</nct_id>
  </id_info>
  <brief_title>Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris</brief_title>
  <acronym>TEAM</acronym>
  <official_title>Efficacy and Safety Comparison of Epiduo Gel Associated With Lymecycline 300 mg Capsules Versus Epiduo Vehicle Gel Associated With Lymecycline 300 mg Capsules in the Treatment of Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Belgium: Institutional Review Board</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>Sweden: Institutional Review Board</authority>
    <authority>Sweden: Swedish Research Council</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Brazil: Ethics Committee</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Mexico: Ethics Committee</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, controlled, multi-center, double-blind, parallel-group comparison study in
      Subjects with moderate to severe acne vulgaris on the face.

      The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% / Benzoyl
      Peroxide (BPO) 2.5% Gel associated with Lymecycline 300mg Capsules compared to Adapalene
      0.1% /Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecycline 300mg Capsules, in the
      treatment of moderate to severe acne vulgaris.

      The safety of the two treatment regimens will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change From Baseline in Total Lesion Count</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from Baseline in Total Lesion count (sum of Non-Inflammatory and Inflammatory lesions) at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success Rate on the Investigator's Global Assessment (IGA) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of Subjects &quot;Clear&quot; or &quot;Almost Clear&quot; on 6-point IGA scale(0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe and 5=very severe) at Week 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adapalene 0.1% / BPO 2.5% gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adapalene 0.1% / BPO 2.5% Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene/ BPO gel with Lymecycline capsules</intervention_name>
    <description>Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning</description>
    <arm_group_label>Adapalene 0.1% / BPO 2.5% gel</arm_group_label>
    <other_name>Adapalene/BPO with Lymecycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene/ BPO vehicle gel with Lymecycline capsules</intervention_name>
    <description>Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning</description>
    <arm_group_label>Adapalene 0.1% / BPO 2.5% Vehicle Gel</arm_group_label>
    <other_name>Adapalene/BPO vehicle with Lymecycline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female Subjects of any race, aged 12 to 35 years inclusive,

          2. Subjects with moderate to severe facial acne vulgaris (Investigator's Global
             Assessment score of 3 or 4),

        Exclusion Criteria:

          1. Subjects with more than 3 nodules or cysts on the face

          2. Subjects with acne conglobata, acne fulminans, secondary acne (chloracne,
             drug-induced acne, etc.),

          3. Subjects with a wash-out period for topical treatment on the face less than:
             Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other
             anti-inflammatory drugs or other acne treatments (2 weeks), Zinc containing drugs (1
             week), Phototherapy devices for acne and cosmetic procedures (1 week)

          4. Subjects with a wash-out period for systemic treatment less than:Acne therapy
             containing zinc (4 weeks), Corticosteroids, antibiotics (4 weeks), Other acne
             treatments (6 months), Ciproterone acetate / Chlormadinone acetate (6 months),
             Spironolactone / Drospirenone (3 months)

          5. Subjects with impaired hepatic (ALT/AST &gt; 3xULN and bilirubin &gt; 1.5xULN) or renal
             (creatinine clearance greater than 60 ml/min) functions based on a blood sample,

          6. Subjects with known intolerance to lactose,
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Paliargues</last_name>
    <role>Study Director</role>
    <affiliation>Galderma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Camberra</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Martigues</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Pantin</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Cuxhaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Mexico city</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Tlalnepantla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Farsta</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigator site</name>
      <address>
        <city>Hagersten</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 17, 2012</lastchanged_date>
  <firstreceived_date>November 16, 2009</firstreceived_date>
  <firstreceived_results_date>August 12, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Lymecycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period 14/08/2009 to 21/01/2010 Type of location: hospital, private hospital and private practice.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adapalene 0.1% / BPO 2.5% Gel + Lymecycline</title>
          <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Adapalene 0.1% / BPO 2.5% Vehicle Gel + Lymecycline</title>
          <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adapalene 0.1% / BPO 2.5% Gel + Lymecycline</title>
          <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Adapalene 0.1% / BPO 2.5% Vehicle Gel + Lymecycline</title>
          <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="191"/>
                <measurement group_id="B2" value="187"/>
                <measurement group_id="B3" value="378"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="113"/>
                <measurement group_id="B2" value="102"/>
                <measurement group_id="B3" value="215"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="78"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="163"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18.6" spread="4.7"/>
                <measurement group_id="B2" value="19.1" spread="4.6"/>
                <measurement group_id="B3" value="18.9" spread="4.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="91"/>
                <measurement group_id="B2" value="78"/>
                <measurement group_id="B3" value="169"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="109"/>
                <measurement group_id="B3" value="209"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mexico</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="104"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Brazil</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Belgium</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Sweden</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Total Lesion Count</title>
        <description>Percent change from Baseline in Total Lesion count (sum of Non-Inflammatory and Inflammatory lesions) at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention to treat - Last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene 0.1% / BPO 2.5% Gel + Lymecycline</title>
            <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adapalene 0.1% / BPO 2.5% Vehicle Gel + Lymecycline</title>
            <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="191"/>
                  <measurement group_id="O2" value="187"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Total Lesion Count</title>
            <description>Percent change from Baseline in Total Lesion count (sum of Non-Inflammatory and Inflammatory lesions) at Week 12.</description>
            <units>percent of change</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-74.1" lower_limit="-100" upper_limit="7.7"/>
                  <measurement group_id="O2" value="-56.8" lower_limit="-97.8" upper_limit="73.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate on the Investigator’s Global Assessment (IGA) at Week 12</title>
        <description>Percentage of Subjects “Clear” or “Almost Clear” on 6-point IGA scale(0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe and 5=very severe) at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention To treat - Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene 0.1% / BPO 2.5% Gel + Lymecycline</title>
            <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adapalene 0.1% / BPO 2.5% Vehicle Gel + Lymecycline</title>
            <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="191"/>
                  <measurement group_id="O2" value="187"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Success Rate on the Investigator’s Global Assessment (IGA) at Week 12</title>
            <description>Percentage of Subjects “Clear” or “Almost Clear” on 6-point IGA scale(0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe and 5=very severe) at Week 12.</description>
            <units>percent of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47.6"/>
                  <measurement group_id="O2" value="33.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks.</time_frame>
      <desc>All clinical medical events, occured after Subject’s consent signed and during the study, whether observed by the Investigator or reported by the Subject and whether or not thought to be product- or study procedure-related were considered adverse events and collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adapalene 0.1% / BPO 2.5% Gel + Lymecycline</title>
          <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Adapalene 0.1% / BPO 2.5% Vehicle Gel + Lymecycline</title>
          <description>Gel applied once daily in the evening during 12 weeks Lymecycline 300mg taken once daily in the morning during 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="191"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure agreement in full force and effect for a period of 10 years.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Florence Paliargues / CPM</name_or_title>
      <organization>Galderma</organization>
      <phone>+33492952957</phone>
      <email>florence.paliargues@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
